-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

HC Wainwright & Co. Maintains Buy on InflaRx, Lowers Price Target to $6

Benzinga · 01/06/2023 04:32
HC Wainwright & Co. analyst Edward White maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $8 to $6.